Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — Q3 2026 Earnings Presentation
14 slides from Halozyme Therapeutics's earnings presentation, Nov 5, 2026
Slide 1: Third Quarter 2026 Financial & Operating Results
Halozyme Therapeutics, Inc. Third Quarter 2026 Financial & Operating Results Nasdaq: HALO November 5, 2026 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking Non-GAAP Financial Measures: statements including, without limitation, statements concerning the Company’s expected future financial performance and growth rates (i
Slide 3: Strong 3Q 2026 Financial and Operating Results Demonstrate Compounding Platform Engine
Strong 3Q 2026 Financial and Operating Results Demonstrate Compounding Platform Engine Commercial ENHANZE® portfolio drove record total revenue of $493 million, representing an increase of 39% year-over-year • Royalty revenue increased 44% year-over-year to $341 million Expanded ENHANZE® collaborati
Slide 4: Building the Next Wave of Royalty Opportunities
Building the Next Wave of Royalty Opportunities EXPANDED AGREEMENTS argenx Added two exclusive ENHANZE® targets, bringing the collaboration to eight targets Incyte Expanded collaboration to evaluate subcutaneous (SC) axalitimab with ENHANZE® Johnson & Johnson Expanded longstanding ENHANZE® collabora
Slide 5: Current Launched ENHANZE Portfolio Driving Growth 2026-2028
Current Launched ENHANZE® Portfolio Driving Growth 2026-2028 Emerging Growth Drivers | Increasing royalty contributions OCREVUS ZUNOVO DARZALEX FASPRO® OPDIVO Qvantig® RYBREVANT FASPRO ✓ 63.5% growth for RYBREVANT plus ✓ ~56,000 patients on OCREVUS ZUNOVO® ✓ SC conversion at 17% LAZCLUZE franchise i
Slide 6: Building the Next Wave of ENHANZE Royalty Opportunities: ENHANZE Clinical Pipeline
Building the Next Wave of ENHANZE® Royalty Opportunities: ENHANZE® Clinical Pipeline Partner Product Indication Phase 1 RECENT CLINICAL argenx ARGX-117 Multifocal Motor Neuropathy ADVANCEMENTS argenx ARGX-119 Undisclosed Pfizer argenx ARGX-121 Nephropathy Tilrekimig SC argenx ARGX-124 Undisclosed ar
Slide 7: Record 3Q 2026 Financial Results
Record 3Q 2026 Financial Results $493.0M $341.0M Total Revenue Royalty Revenue +39% +44% $2.39 $336.2M Non-GAAP Adjusted EBITDA1 Diluted EPS1 +35% +39% $1.5 billion Convertible Note 1 Reconciliation between GAAP reported and Non-GAAP financial information for actual results are provided at the end 7
Slide 8: Robust ENHANZE Royalty Revenue Growth Opportunity
Robust ENHANZE® Royalty Revenue Growth Opportunity Total DARZALEX® IV+SC Revenue VYVGART® & VYVGART® Hytrulo Revenue PHESGO® Revenue Based on Analyst Estimates 1 Based on Analyst Estimates2 Based on Analyst Estimates1 ($B) ($B) ($B) $21.0 $8.6 $3.5 $3.6 $3.6 $19.2 $7.2 $3.0 $17.0 $14.4 $5.9 $4.1 202
Slide 9: 3Q 2026 Financial Highlights
3Q 2026 Financial Highlights $ in Millions, except EPS (unaudited) 3Q 2026 3Q 2025 % Change Royalties $341.0 $236.0 44% Product sales, net $137.3 $94.2 46% Collaboration revenues $14.6 $24.0 (39)% Total Revenues $493.0 $354.3 39% Cost of sales $82.5 $55.2 49% Amortization of intangibles $29.5 $17.8
Slide 10: Substantial Cash Flow Generation Provides Significant Flexibility for Disciplined Capital Allocation
Substantial Cash Flow Generation Provides Significant Flexibility for Disciplined Capital Allocation Maximize Organic Return Capital to Deleveraging M&A Investments Shareholders Plan to retire the 2027 and 2028 remaining notes at Repurchased $400 million in maturity Maximize the value of 2026, as pa
Slide 11: Raising FY 2026 Guidance Ranges
Raising FY 2026 Guidance Ranges 2025 Prior 2026 Updated 2026 YOY Actuals GUIDANCE1 GUIDANCE CHANGE (%) • Product sales to be relatively flat sequentially as growth in proprietary sales is partially offset by Total partner product sales order timing $1,396.6 $1.835B – 1.910B $1.860B – 1.925B 33% – 38
Slide 12: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations 12
Slide 13: GAAP to Non-GAAP Reconciliation: EBITDA and Adjusted EBITDA
GAAP to Non-GAAP Reconciliation: EBITDA and Adjusted EBITDA $ in thousands (Unaudited) (1) Amount represents incremental costs including legal and advisory fees incurred in association with the acquisition of Elektrofi. (2) Adjustment relates to litigation costs incurred by Halozyme in connection wi
Slide 14: GAAP to Non-GAAP Reconciliation: Net Income and Diluted EPS
GAAP to Non-GAAP Reconciliation: Net Income and Diluted EPS $ in thousands, except per share amounts (Unaudited) (1) Amount represents incremental costs including legal and advisory fees incurred in association with the acquisition of Elektrofi. (2) Adjustment relates to litigation costs incurred by
Halozyme Therapeutics — Q3 2026 Earnings Presentation on 6ix